These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 34207556)

  • 41. Evolving neoantigen profiles in colorectal cancers with DNA repair defects.
    Rospo G; Lorenzato A; Amirouchene-Angelozzi N; Magrì A; Cancelliere C; Corti G; Negrino C; Amodio V; Montone M; Bartolini A; Barault L; Novara L; Isella C; Medico E; Bertotti A; Trusolino L; Germano G; Di Nicolantonio F; Bardelli A
    Genome Med; 2019 Jun; 11(1):42. PubMed ID: 31253177
    [TBL] [Abstract][Full Text] [Related]  

  • 42. dbPepNeo: a manually curated database for human tumor neoantigen peptides.
    Tan X; Li D; Huang P; Jian X; Wan H; Wang G; Li Y; Ouyang J; Lin Y; Xie L
    Database (Oxford); 2020 Jan; 2020():. PubMed ID: 32090262
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Neoantigen Targeting-Dawn of a New Era in Cancer Immunotherapy?
    Wirth TC; Kühnel F
    Front Immunol; 2017; 8():1848. PubMed ID: 29312332
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Immunoglobulin somatic hypermutation has clinical impact in DLBCL and potential implications for immune checkpoint blockade and neoantigen-based immunotherapies.
    Xu-Monette ZY; Li J; Xia Y; Crossley B; Bremel RD; Miao Y; Xiao M; Snyder T; Manyam GC; Tan X; Zhang H; Visco C; Tzankov A; Dybkaer K; Bhagat G; Tam W; You H; Hsi ED; van Krieken JH; Huh J; Ponzoni M; Ferreri AJM; Møller MB; Piris MA; Winter JN; Medeiros JT; Xu B; Li Y; Kirsch I; Young KH
    J Immunother Cancer; 2019 Oct; 7(1):272. PubMed ID: 31640780
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Neoantigen vaccine: an emerging tumor immunotherapy.
    Peng M; Mo Y; Wang Y; Wu P; Zhang Y; Xiong F; Guo C; Wu X; Li Y; Li X; Li G; Xiong W; Zeng Z
    Mol Cancer; 2019 Aug; 18(1):128. PubMed ID: 31443694
    [TBL] [Abstract][Full Text] [Related]  

  • 46. MHC class II restricted neoantigen: A promising target in tumor immunotherapy.
    Sun Z; Chen F; Meng F; Wei J; Liu B
    Cancer Lett; 2017 Apr; 392():17-25. PubMed ID: 28104443
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Advances in personalized neoantigen vaccines for cancer immunotherapy.
    Sun C; Xu S
    Biosci Trends; 2020 Nov; 14(5):349-353. PubMed ID: 32908077
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Contribution of systemic and somatic factors to clinical response and resistance to PD-L1 blockade in urothelial cancer: An exploratory multi-omic analysis.
    Snyder A; Nathanson T; Funt SA; Ahuja A; Buros Novik J; Hellmann MD; Chang E; Aksoy BA; Al-Ahmadie H; Yusko E; Vignali M; Benzeno S; Boyd M; Moran M; Iyer G; Robins HS; Mardis ER; Merghoub T; Hammerbacher J; Rosenberg JE; Bajorin DF
    PLoS Med; 2017 May; 14(5):e1002309. PubMed ID: 28552987
    [TBL] [Abstract][Full Text] [Related]  

  • 49. ProGeo-neo: a customized proteogenomic workflow for neoantigen prediction and selection.
    Li Y; Wang G; Tan X; Ouyang J; Zhang M; Song X; Liu Q; Leng Q; Chen L; Xie L
    BMC Med Genomics; 2020 Apr; 13(Suppl 5):52. PubMed ID: 32241270
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparison of personal and shared frameshift neoantigen vaccines in a mouse mammary cancer model.
    Peterson M; Murphy SN; Lainson J; Zhang J; Shen L; Diehnelt CW; Johnston SA
    BMC Immunol; 2020 May; 21(1):25. PubMed ID: 32370785
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Peptide vaccines in early breast cancer.
    Criscitiello C; Viale G; Curigliano G
    Breast; 2019 Apr; 44():128-134. PubMed ID: 30769238
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Reduced Neoantigen Expression Revealed by Longitudinal Multiomics as a Possible Immune Evasion Mechanism in Glioma.
    Nejo T; Matsushita H; Karasaki T; Nomura M; Saito K; Tanaka S; Takayanagi S; Hana T; Takahashi S; Kitagawa Y; Koike T; Kobayashi Y; Nagae G; Yamamoto S; Ueda H; Tatsuno K; Narita Y; Nagane M; Ueki K; Nishikawa R; Aburatani H; Mukasa A; Saito N; Kakimi K
    Cancer Immunol Res; 2019 Jul; 7(7):1148-1161. PubMed ID: 31088845
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Characterization of Neoantigen Load Subgroups in Gynecologic and Breast Cancers.
    Zhu Y; Meng X; Ruan X; Lu X; Yan F; Wang F
    Front Bioeng Biotechnol; 2020; 8():702. PubMed ID: 32754579
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Improved Survival of a HER2-Positive Metastatic Breast Cancer Patient Following a Personalized Peptide Immunization.
    Schönharting W; Roehnisch T; Manoochehri M; Christoph J; Sieger M; Nogueira M; Martos-Contreras MC; Kunz M
    Vaccines (Basel); 2023 May; 11(6):. PubMed ID: 37376412
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Gut metabolite mediates neoantigen generation in AS.
    McHugh J
    Nat Rev Rheumatol; 2023 Jun; 19(6):325. PubMed ID: 37161086
    [No Abstract]   [Full Text] [Related]  

  • 56. Erratum for the Research Article "A functional identification platform reveals frequent, spontaneous neoantigen-specific T cell responses in patients with cancer" by A. M. Miller
    Sci Transl Med; 2024 May; 16(746):eadp8153. PubMed ID: 38718137
    [No Abstract]   [Full Text] [Related]  

  • 57. Correction to: NeoFox: annotating neoantigen candidates with neoantigen features.
    Bioinformatics; 2023 Dec; 39(12):. PubMed ID: 38140710
    [No Abstract]   [Full Text] [Related]  

  • 58. Author Correction: Molecular mechanism of phosphopeptide neoantigen immunogenicity.
    Patskovsky Y; Natarajan A; Patskovska L; Nyovanie S; Joshi B; Morin B; Brittsan C; Huber O; Gordon S; Michelet X; Schmitzberger F; Stein RB; Findeis MA; Hurwitz A; Van Dijk M; Chantzoura E; Yague AS; Pollack Smith D; Buell JS; Underwood D; Krogsgaard M
    Nat Commun; 2023 Jul; 14(1):4522. PubMed ID: 37500629
    [No Abstract]   [Full Text] [Related]  

  • 59. Update Breast Cancer 2022 Part 5 - Early Stage Breast Cancer.
    Fehm TN; Welslau M; Müller V; Lüftner D; Schütz F; Fasching PA; Janni W; Thomssen C; Witzel I; Beierlein M; Belleville E; Untch M; Thill M; Tesch H; Ditsch N; Lux MP; Aktas B; Banys-Paluchowski M; Kolberg-Liedtke C; Hartkopf AD; Wöckel A; Kolberg HC; Harbeck N; Stickeler E
    Geburtshilfe Frauenheilkd; 2023 Mar; 83(3):289-298. PubMed ID: 36908285
    [TBL] [Abstract][Full Text] [Related]  

  • 60. In silico designed mRNA vaccines targeting CA-125 neoantigen in breast and ovarian cancer.
    Lu L; Ma W; Johnson CH; Khan SA; Irwin ML; Pusztai L
    Vaccine; 2023 Mar; 41(12):2073-2083. PubMed ID: 36813666
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.